SymBio Pharmaceuticals Limited
JPX: 4582.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Fuminori Yoshida
- Employees
- 108
- Headquarters
- Tokyo, Japan
- IPO year
- 2011
- Market cap
- ¥4.6B
- Website
- https://www.symbiopharma.com
Loading 4582…
Loading profile data…Frequently asked questions about 4582
What does SymBio Pharmaceuticals Limited (4582.T) do?
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chroni...
Where does 4582.T trade?
SymBio Pharmaceuticals Limited (4582.T) trades on the Tokyo Stock Exchange.
What sector is 4582.T in?
SymBio Pharmaceuticals Limited (4582.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of SymBio Pharmaceuticals Limited?
Fuminori Yoshida is the chief executive officer of SymBio Pharmaceuticals Limited (4582.T).
Where is SymBio Pharmaceuticals Limited headquartered?
SymBio Pharmaceuticals Limited is headquartered in Japan.
Does 4582.T pay a dividend?
SymBio Pharmaceuticals Limited (4582.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4582.T go public?
SymBio Pharmaceuticals Limited (4582.T) completed its initial public offering in 2011.